Comparative Pharmacology
Head-to-head clinical analysis: QALSODY versus SPINRAZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QALSODY versus SPINRAZA.
QALSODY vs SPINRAZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
QALSODY (tofersen) is an antisense oligonucleotide that mediates degradation of SOD1 mRNA through RNase H activity, reducing SOD1 protein production.
SPINRAZA (nusinersen) is an antisense oligonucleotide that modifies splicing of pre-messenger RNA of the survival motor neuron 2 (SMN2) gene to increase production of full-length SMN protein, which is deficient in spinal muscular atrophy (SMA).
100 mg intrathecally once every 4 weeks. Administer as a loading dose of 100 mg on days 0, 14, and 28, then every 4 weeks thereafter.
Loading dose: 12 mg (5 mL) intrathecally on days 0, 14, 28, and 63. Maintenance dose: 12 mg (5 mL) intrathecally once every 4 months.
None Documented
None Documented
Terminal elimination half-life is approximately 28 days (range 22-35 days) following intrathecal administration; this prolonged half-life supports monthly dosing schedules and reflects slow clearance from the central nervous system.
Terminal elimination half-life in cerebrospinal fluid (CSF) is 135–177 days; in plasma, it is 63–87 days. The long CSF half-life supports monthly intrathecal dosing.
Primarily excreted unchanged in urine via glomerular filtration and tubular secretion, accounting for approximately 60-70% of the administered dose; biliary/fecal excretion accounts for the remainder (30-40%) as inactive metabolites and parent drug.
Primarily metabolized via exonuclease-mediated hydrolysis; renal excretion of intact drug is negligible (<1%). No biliary or fecal elimination is documented.
Category C
Category C
Antisense Oligonucleotide
Antisense Oligonucleotide